Ceftaroline activity tested against bacterial isolates from pediatric patients results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012)

Pediatric Infectious Disease Journal

Volumn 33, Issue 8, 2014, Pages 837-842

  Sader, Helio S ^a   Mendes, Rodrigo E ^a   Farrell, David J ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

AWARE; Ceftaroline; MRSA; Streptococcus pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE;

ADOLESCENT; ANTIBIOTIC RESISTANCE; BACTERIAL SKIN DISEASE; BACTERIUM; CHILD; DRUG EFFECTS; HUMAN; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEWBORN; PRESCHOOL CHILD; SEROTYPING; SOFT TISSUE INFECTION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; SEROTYPING; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84905827494     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000307     Document Type: Review

References (28)

1. Jacobs MR, Dagan R. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. Semin Pediatr Infect Dis. 2004;15:5-20.
2. Versporten A, Sharland M, Bielicki J, et al.; ARPEC Project Group Members. The antibiotic resistance and prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide. Pediatr Infect Dis J. 2013;32:e242-e253.
3. Long CB, Madan RP, Herold BC. Diagnosis and management of community-associated MRSA infections in children. Expert Rev Anti Infect Ther. 2010;8:183-195.
4. Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin Pediatr Infect Dis. 2006;17:113-119.
5. Critchley IA, Eckburg PB, Jandourek A, et al. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother. 2011;66 Suppl 3:iii45-iii51.
6. Frampton JE. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs. 2013;73:1067-1094.
7. Lodise TP, Low DE. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs. 2012;72:1473-1493.
8. Teflaro® Package Insert. Teflaro® Package Insert. 2012. Available at: http:// www.accessdata.fda.gov/drugsatfda-docs/label/2013/200327s009lbl. pdf. Accessed August 2013.
9. ZinforoTM Package Insert. ZinforoTM Package Insert. 2012. Available at: http:// www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002252/WC500132586.pdf. Accessed January 2013.
10. Farrell DJ, Castanheira M, Mendes RE, et al. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008-2010). Clin Infect Dis. 2012;55 (Suppl 3):S206-S214.
11. CLSI. M07-A9. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Ninth edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
12. CLSI. M100-S23. Performance Standards for Antimicrobial Susceptibility Testing: 23rd Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
13. Leung MH, Bryson K, Freystatter K, et al. Sequetyping: serotyping Streptococcus pneumoniae by a single PCR sequencing strategy. J Clin Microbiol. 2012;50:2419-2427.
14. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006;44:124-131.
15. Bradley JS, Byington CL, Shah SS, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:617-630.
16. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616-687.
17. Hinckley J, Allen PJ. Community-associated MRSA in the pediatric primary care setting. Pediatr Nurs. 2008;34:64-71.
18. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother. 2009;64:441-446.
19. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279:593-598.
20. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148:249-257.
21. Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin Microbiol Infect. 2009;15:224-231.
22. Sader HS, Flamm RK, Farrell DJ, et al. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. Clin Infect Dis. 2012;55(Suppl 3):S181-S186.
23. Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 2010;54:2716-2719.
24. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2010;36:197-204.
25. Jones RN, Sader HS, Mendes RE, et al. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis. 2013;75:107-109.
26. Pfaller MA, Farrell DJ, Sader HS, et al. AWARE ceftaroline surveillance program (2008-2010); trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis. 2012;55 (Suppl 3):S187-S193.
27. Castanheira M, Farrell SE, Deshpande LM, et al. Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother. 2013;57:3012-3020.
28. Flamm RK, Sader HS, Farrell DJ, et al. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother. 2012;56:2933-2940.